Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Muscle Invasive Bladder Cancer 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Disease 1 Advanced Solid Malignancies 1 Advanced Metastatic Breast Cancer 1 Advanced Cancer 1

Interventions

Docetaxel 43 enzalutamide 31 Prednisone 25 Abiraterone Acetate 24 Magnetic Resonance Spectroscopy 18 abiraterone 15 pembrolizumab 14 bicalutamide 14 Radiotherapy 14 Cyclophosphamide 13 darolutamide 12 Leuprolide 12 Goserelin 12 apalutamide 10 Ipilimumab 10 olaparib 9 Specimen Handling 9 Radiosurgery 9 Radiation 9 Injections 9 Biopsy 9 Pluvicto 8 Paclitaxel 8 Radiotherapy, Intensity-Modulated 7 Carboplatin 7 sargramostim 6 fludarabine 6 cabazitaxel 6 Sirolimus 6 Nivolumab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Prostatic Neoplasms × vistusertib × Clear all

NCT02064608 2019-07-17

CaNCaP02

Cambridge University Hospitals NHS Foundation Trust

Phase 1 Completed

Disease, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡